

# House Bill 3466

Sponsored by Representative THOMPSON; Representatives KENY-GUYER, KOMP

## SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure **as introduced**.

Authorizes pharmacist to initiate or modify drug therapy in accordance with guidelines and protocols established by physician licensed to practice medicine. Specifies guidelines and protocols that must be followed. Prohibits pharmacist from initiating or modifying drug therapy for drugs that are controlled substances classified in Schedules I through IV of federal Controlled Substances Act.

Authorizes pharmacist to substitute, under certain conditions, prescribed drug with therapeutically equivalent drug in accordance with rules adopted by State Board of Pharmacy.

Clarifies provision authorizing prescriptive authority with respect to Schedule II controlled substances.

## A BILL FOR AN ACT

1  
2 Relating to the practice of pharmacy; creating new provisions; and amending ORS 475.185, 475.188,  
3 689.005 and 689.515.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1.** ORS 689.005 is amended to read:

6 689.005. As used in this chapter:

7 (1) "Administer" means the direct application of a drug or device whether by injection,  
8 inhalation, ingestion, or any other means, to the body of a patient or research subject by:

9 (a) A practitioner or the practitioner's authorized agent; or

10 (b) The patient or research subject at the direction of the practitioner.

11 (2) "Approved continuing pharmacy education program" means those seminars, classes,  
12 meetings, workshops and other educational programs on the subject of pharmacy approved by the  
13 board.

14 (3) "Board of pharmacy" or "board" means the State Board of Pharmacy.

15 (4) "Continuing pharmacy education" means:

16 (a) Professional, pharmaceutical post-graduate education in the general areas of socio-economic  
17 and legal aspects of health care;

18 (b) The properties and actions of drugs and dosage forms; and

19 (c) The etiology, characteristics and therapeutics of the disease state.

20 (5) "Continuing pharmacy education unit" means the unit of measurement of credits for ap-  
21 proved continuing education courses and programs.

22 (6) "Deliver" or "delivery" means the actual, constructive or attempted transfer of a drug or  
23 device other than by administration from one person to another, whether or not for a consideration.

24 (7) "Device" means an instrument, apparatus, implement, machine, contrivance, implant, in vitro  
25 reagent or other similar or related article, including any component part or accessory, which is re-  
26 quired under federal or state law to be prescribed by a practitioner and dispensed by a pharmacist.

27 (8) "Dispense" or "dispensing" means the preparation and delivery of a prescription drug pur-  
28 suant to a lawful order of a practitioner in a suitable container appropriately labeled for subsequent

**NOTE:** Matter in **boldfaced** type in an amended section is new; matter *[italic and bracketed]* is existing law to be omitted. New sections are in **boldfaced** type.

1 administration to or use by a patient or other individual entitled to receive the prescription drug.

2 (9) "Distribute" means the delivery of a drug other than by administering or dispensing.

3 (10) "Drug" means:

4 (a) Articles recognized as drugs in the official United States Pharmacopoeia, official National  
5 Formulary, official Homeopathic Pharmacopoeia, other drug compendium or any supplement to any  
6 of them;

7 (b) Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of dis-  
8 ease in a human or other animal;

9 (c) Articles, other than food, intended to affect the structure or any function of the body of hu-  
10 mans or other animals; and

11 (d) Articles intended for use as a component of any articles specified in paragraph (a), (b) or (c)  
12 of this subsection.

13 (11) "Drug order" means a written order, in a hospital or other inpatient care facility, for an  
14 ultimate user of any drug or device issued and signed by a practitioner, or an order transmitted by  
15 other means of communication from a practitioner, that is immediately reduced to writing by a  
16 pharmacist, licensed nurse or other practitioner.

17 (12) "Drug outlet" means any pharmacy, nursing home, shelter home, convalescent home, ex-  
18 tended care facility, drug abuse treatment center, penal institution, hospital, family planning clinic,  
19 student health center, retail store, wholesaler, manufacturer, mail-order vendor or other establish-  
20 ment with facilities located within or out of this state that is engaged in dispensing, delivery or  
21 distribution of drugs within this state.

22 (13) "Drug room" means a secure and lockable location within an inpatient care facility that  
23 does not have a licensed pharmacy.

24 (14) "Electronically transmitted" or "electronic transmission" means a communication sent or  
25 received through technological apparatuses, including computer terminals or other equipment or  
26 mechanisms linked by telephone or microwave relays, or any similar apparatus having electrical,  
27 digital, magnetic, wireless, optical, electromagnetic or similar capabilities.

28 (15) "Institutional drug outlet" means hospitals and inpatient care facilities where medications  
29 are dispensed to another health care professional for administration to patients served by the hos-  
30 pitals or facilities.

31 (16) "Intern" means a person who is enrolled in or has completed a course of study at a school  
32 or college of pharmacy approved by the board and who is licensed with the board as an intern.

33 (17) "Internship" means a professional experiential program approved by the board under the  
34 supervision of a licensed pharmacist registered with the board as a preceptor.

35 (18) "Itinerant vendor" means a person who sells or distributes nonprescription drugs by passing  
36 from house to house, or by haranguing the people on the public streets or in public places, or who  
37 uses the customary devices for attracting crowds, recommending their wares and offering them for  
38 sale.

39 (19) "Labeling" means the process of preparing and affixing of a label to any drug container  
40 exclusive, however, of the labeling by a manufacturer, packer or distributor of a nonprescription  
41 drug or commercially packaged legend drug or device.

42 (20) "Manufacture" means the production, preparation, propagation, compounding, conversion  
43 or processing of a device or a drug, either directly or indirectly by extraction from substances of  
44 natural origin or independently by means of chemical synthesis or by a combination of extraction  
45 and chemical synthesis and includes any packaging or repackaging of the substances or labeling or

1 relabeling of its container, except that this term does not include the preparation or compounding  
 2 of a drug by an individual for their own use or the preparation, compounding, packaging or labeling  
 3 of a drug:

4 (a) By a practitioner as an incident to administering or dispensing of a drug in the course of  
 5 professional practice; or

6 (b) By a practitioner or by the practitioner's authorization under supervision of the practitioner  
 7 for the purpose of or as an incident to research, teaching or chemical analysis and not for sale.

8 (21) "Manufacturer" means a person engaged in the manufacture of drugs.

9 (22) "Nonprescription drug outlet" means shopkeepers and itinerant vendors registered under  
 10 ORS 689.305.

11 (23) "Nonprescription drugs" means drugs which may be sold without a prescription and which  
 12 are prepackaged for use by the consumer and labeled in accordance with the requirements of the  
 13 statutes and regulations of this state and the federal government.

14 (24) "Person" means an individual, corporation, partnership, association or any other legal en-  
 15 tity.

16 (25) "Pharmacist" means an individual licensed by this state to engage in the practice of phar-  
 17 macy.

18 (26) "Pharmacy" means a place that meets the requirements of rules of the board, is licensed  
 19 and approved by the board where the practice of pharmacy may lawfully occur and includes  
 20 apothecaries, drug stores, dispensaries, hospital outpatient pharmacies, pharmacy departments and  
 21 prescription laboratories but does not include a place used by a manufacturer or wholesaler.

22 (27) "Pharmacy technician" means a person licensed by the State Board of Pharmacy who assists  
 23 the pharmacist in the practice of pharmacy pursuant to rules of the board.

24 (28) "Practice of pharmacy" means:

25 (a) The interpretation and evaluation of prescription orders;

26 (b) The compounding, dispensing and labeling of drugs and devices, except labeling by a man-  
 27 ufacturer, packer or distributor of nonprescription drugs and commercially packaged legend drugs  
 28 and devices;

29 (c) The prescribing and administering of vaccines and immunizations pursuant to ORS 689.645;

30 (d) The administering of drugs and devices to the extent permitted under ORS 689.655;

31 (e) The participation in drug selection and drug utilization reviews;

32 (f) The proper and safe storage of drugs and devices and the maintenance of proper records  
 33 therefor;

34 (g) The responsibility for advising, where necessary or where regulated, of therapeutic values,  
 35 content, hazards and use of drugs and devices;

36 (h) The monitoring of therapeutic response or adverse effect to drug therapy; [and]

37 (i) **The initiation or modification of drug therapy as described in section 3 of this 2013**  
 38 **Act; and**

39 [(i)] (j) The offering or performing of those acts, services, operations or transactions necessary  
 40 in the conduct, operation, management and control of pharmacy.

41 (29) "Practitioner" means a person licensed and operating within the scope of such license to  
 42 prescribe, dispense, conduct research with respect to or administer drugs in the course of profes-  
 43 sional practice or research:

44 (a) In this state; or

45 (b) In another state or territory of the United States if the person does not reside in Oregon and

1 is registered under the federal Controlled Substances Act.

2 (30) "Preceptor" means a pharmacist or a person licensed by the board to supervise the  
3 internship training of a licensed intern.

4 (31) "Prescription drug" or "legend drug" means a drug which is:

5 (a) Required by federal law, prior to being dispensed or delivered, to be labeled with either of  
6 the following statements:

7 (A) "Caution: Federal law prohibits dispensing without prescription"; or

8 (B) "Caution: Federal law restricts this drug to use by or on the order of a licensed  
9 veterinarian"; or

10 (b) Required by any applicable federal or state law or regulation to be dispensed on prescription  
11 only or is restricted to use by practitioners only.

12 (32) "Prescription" or "prescription drug order" means a written, oral or electronically trans-  
13 mitted direction, given by a practitioner authorized to prescribe drugs, for the preparation and use  
14 of a drug. When the context requires, "prescription" also means the drug prepared under such  
15 written, oral or electronically transmitted direction.

16 (33) "Retail drug outlet" means a place used for the conduct of the retail sale, administering or  
17 dispensing or compounding of drugs or chemicals or for the administering or dispensing of pre-  
18 scriptions and licensed by the board as a place wherein the practice of pharmacy may lawfully oc-  
19 cur.

20 (34) "Shopkeeper" means a business or other establishment, open to the general public, for the  
21 sale or nonprofit distribution of drugs.

22 (35) "Unit dose" means a sealed single-unit container so designed that the contents are admin-  
23 istered to the patient as a single dose, direct from the container. Each unit dose container must bear  
24 a separate label, be labeled with the name and strength of the medication, the name of the man-  
25 ufacturer or distributor, an identifying lot number and, if applicable, the expiration date of the  
26 medication.

27 (36) "Wholesale drug outlet" means any person who imports, stores, distributes or sells for re-  
28 sale any drugs including legend drugs and nonprescription drugs.

29 **SECTION 2. Section 3 of this 2013 Act is added to and made a part of ORS chapter 689.**

30 **SECTION 3. (1)(a) Except as provided in paragraph (b) of this subsection, a pharmacist**  
31 **may initiate or modify drug therapy in accordance with guidelines and protocols established**  
32 **by a physician licensed to practice medicine under ORS chapter 677 if the guidelines and**  
33 **protocols are in compliance with the provisions of this section.**

34 **(b) A pharmacist may not initiate or modify drug therapy for a drug that is a controlled**  
35 **substance classified in Schedules I through IV under the federal Controlled Substances Act,**  
36 **21 U.S.C. 811 and 812, as modified under ORS 475.035.**

37 **(2) Guidelines and protocols established under this section must contain, at a minimum:**

38 **(a) The identities of the physician and the pharmacist;**

39 **(b) The time period, not to exceed two years, during which the pharmacist may initiate**  
40 **or modify drug therapy;**

41 **(c) The scope of the pharmacist's prescriptive authority, including:**

42 **(A) The types of injuries, illnesses or diseases for which the pharmacist may initiate or**  
43 **modify drug therapy; and**

44 **(B) The types of drugs that the pharmacist may prescribe for those injuries, illnesses or**  
45 **diseases;**

1       **(d) The procedures that the pharmacist must follow and the criteria that the pharmacist**  
2 **must consider when initiating or modifying drug therapy; and**

3       **(e) The procedures that the pharmacist must follow after initiating or modifying drug**  
4 **therapy, including:**

5       **(A) The procedures for documenting the initiation or modification;**

6       **(B) The means of documenting the initiation or modification; and**

7       **(C) The procedures for communicating the initiation or modification to the physician.**

8       **SECTION 4.** ORS 689.515 is amended to read:

9       689.515. (1) As used in this section unless the context requires otherwise:

10       (a) "Brand name" means the proprietary or trade name selected by the manufacturer and placed  
11 upon a drug, its container, label or wrapping at the time of packaging.

12       (b) "Dosage form" means the physical formulation or medium in which the product is intended,  
13 manufactured and made available for use, including but not limited to tablets, capsules, oral sol-  
14 utions, aerosols, ointments, inhalers and suppositories, and the particular form of which utilizes a  
15 specific technology or mechanism to control, enhance or direct the release, targeting, systemic ab-  
16 sorption or other delivery of a dosage regimen in the body.

17       (c) "Generic name" means the official title of a drug or drug ingredients published in the latest  
18 edition of the official Pharmacopoeia, Homeopathic Pharmacopoeia or Formulary.

19       (d) "Substitute" means to dispense without the prescriber's express authorization a different  
20 drug product in place of the drug ordered or prescribed.

21       (e) "Therapeutically equivalent" means drugs that are approved by the United States Food and  
22 Drug Administration for interstate distribution and the Food and Drug Administration has deter-  
23 mined that the drugs will provide essentially the same efficacy and toxicity when administered to  
24 an individual in the same dosage regimen.

25       (2) Except as limited by subsections (3) and (5) of this section, unless the purchaser instructs  
26 otherwise, a pharmacist may substitute as follows:

27       (a) A drug product with the same generic name in the same strength, quantity, dose and dosage  
28 form as the prescribed drug which is, in the pharmacist's professional opinion, therapeutically  
29 equivalent.

30       (b) When the prescriber is not reasonably available for consultation and the prescribed drug  
31 does not utilize a unique delivery system technology, an oral tablet, capsule or liquid form of the  
32 prescribed drug so long as the form dispensed or administered has the same strength, dose and dose  
33 schedule and is therapeutically equivalent to the drug prescribed.

34       **(c) A drug that is therapeutically equivalent to the drug prescribed as established by the**  
35 **State Board of Pharmacy by rule.**

36       (3) A practitioner may specify in writing, by a telephonic communication or by electronic  
37 transmission that there may be no substitution for the specified brand name drug in a prescription.

38       (4) A pharmacy shall post a sign in a location easily seen by patrons at the counter where  
39 prescriptions are dispensed or administered stating that, "This pharmacy may be able to substitute  
40 a less expensive drug which is therapeutically equivalent to the one prescribed by your doctor un-  
41 less you do not approve." The printing on the sign must be in block letters not less than one inch  
42 in height. If the pharmacist has reasonable cause to believe that the purchaser cannot read the sign  
43 or comprehend its content, the pharmacist shall endeavor to explain the meaning of the sign.

44       (5) A pharmacist may substitute a drug product under this section only when there will be a  
45 savings in or no increase in cost to the purchaser.

1 (6) If the practitioner prescribes a drug by its generic name, the pharmacist shall, consistent  
 2 with reasonable professional judgment, dispense or administer the lowest retail cost, effective brand  
 3 which is in stock.

4 (7) Except as provided in subsection (8) of this section, when a pharmacist dispenses a substi-  
 5 tuted drug as authorized by subsection (2) of this section, the pharmacist shall label the prescription  
 6 container with the name of the dispensed drug. If the dispensed drug does not have a brand name,  
 7 the pharmacist shall label the prescription container with the generic name of the drug dispensed  
 8 along with the name of the drug manufacturer.

9 (8) A prescription dispensed by a pharmacist must bear upon the label the name of the  
 10 medication in the container or shall be labeled as intended by the prescriber.

11 (9) The substitution of any drug by a pharmacist or the pharmacist's employer pursuant to this  
 12 section does not constitute the practice of medicine.

13 (10) A substitution of drugs made by a pharmacist or the pharmacist's employer in accordance  
 14 with this section and any rules that the [State] board [of Pharmacy] may adopt thereunder does not  
 15 constitute evidence of negligence if the substitution was made within reasonable and prudent prac-  
 16 tice of pharmacy or if the substituted drug was accepted in a generally recognized formulary or  
 17 government list.

18 (11) Failure of a practitioner to specify that no substitution is authorized does not constitute  
 19 evidence of negligence unless the practitioner knows that the health condition of the patient for  
 20 whom the practitioner is prescribing warrants the use of the brand name drug product and not the  
 21 substituted drug.

22 **SECTION 5.** ORS 475.185 is amended to read:

23 475.185. [(1) Except when dispensed directly by a practitioner to an ultimate user, a controlled  
 24 substance in Schedule II may not be dispensed without the written prescription of a practitioner.]

25 [(2)] (1) In emergency situations, as defined by rule of the State Board of Pharmacy, Schedule  
 26 II drugs may be dispensed upon oral or electronically transmitted prescription of a practitioner, re-  
 27 duced promptly to writing and filed by the pharmacy. Prescriptions shall be retained in conformity  
 28 with the requirements of ORS 475.165. A prescription for a Schedule II substance may not be re-  
 29 filled.

30 [(3)] (2) Except when dispensed directly by a practitioner to an ultimate user, a controlled sub-  
 31 stance included in Schedule II, III or IV may not be dispensed without a written, oral or electron-  
 32 ically transmitted prescription of a practitioner. The prescription **for a controlled substance in**  
 33 **Schedule II may not be refilled. Additional quantities of a controlled substance in Schedule**  
 34 **II may be authorized by a practitioner only through issuance of a new prescription. The**  
 35 **prescription for a controlled substance in Schedule III or IV** may not be filled or refilled more  
 36 than six months after the date on which it was issued and a prescription authorized to be refilled  
 37 may not be refilled more than five times. Additional quantities of the controlled substances listed  
 38 in Schedule III or IV may [only] be authorized by a practitioner **only** through issuance of a new  
 39 prescription.

40 [(4)] (3) Except when dispensed directly by a practitioner to an ultimate user, a controlled sub-  
 41 stance included in Schedule V that is a prescription drug may not be dispensed without a written,  
 42 oral or electronically transmitted prescription of a practitioner. The prescription may not be filled  
 43 or refilled more than six months after the date on which it was issued and a prescription authorized  
 44 to be refilled may not be refilled more than five times. Additional quantities of the controlled sub-  
 45 stances listed in Schedule V may [only] be authorized by a practitioner **only** through issuance of a

1 new prescription.

2 [(5)] (4) A controlled substance may not be delivered or dispensed other than for a medical  
3 purpose.

4 [(6)] (5) Except in good faith and in the course of professional practice only, a practitioner or  
5 a pharmacist may not dispense controlled substances.

6 [(7)] (6) Any oral or electronically transmitted prescription authorized by statute or rule must  
7 be stored by electronic means or reduced promptly to writing and filed by the pharmacy.

8 [(8)] (7) Issuance, preparation, labeling, dispensing, recordkeeping and filing of prescriptions or  
9 medication orders must be in conformance with the requirements of the federal law and rules of the  
10 board.

11 **SECTION 6.** ORS 475.188 is amended to read:

12 475.188. (1) Prescription drug orders may be transmitted by electronic means from a practitioner  
13 authorized to prescribe drugs directly to the dispensing pharmacist.

14 (2) All prescription drug orders communicated by way of electronic transmission shall:

15 (a) Be transmitted only by an authorized practitioner;

16 (b) Be transmitted directly to a pharmacist in a pharmacy of the patient's choice with no in-  
17 tervening person having access to the prescription drug order;

18 (c) Specify the prescribing practitioner's telephone number for verbal confirmation, the time and  
19 date of transmission, the identity of the pharmacy intended to receive the transmission and all other  
20 information required for a prescription by federal or state law; and

21 (d) Be traceable to the prescribing practitioner by an electronic signature or other secure  
22 method of validation.

23 (3) An electronic transmission of a prescription drug order shall be stored by electronic means  
24 or reduced promptly to writing, filed by the pharmacy and retained in conformity with the require-  
25 ments of ORS 475.165.

26 (4) The dispensing pharmacist shall exercise professional judgment regarding the accuracy, va-  
27 lidity and authenticity of an electronically transmitted prescription drug order.

28 (5) All equipment for transmission, storage or receipt of electronically transmitted prescription  
29 drug orders shall be maintained to protect against unauthorized access.

30 (6) A pharmacist, pharmacy or pharmacy department shall not enter into an agreement with a  
31 practitioner or health care facility concerning the provision of any electronic transmission equip-  
32 ment or apparatus that would adversely affect a patient's freedom to select the pharmacy or phar-  
33 macy department of the patient's choice.

34 (7) A pharmacist, pharmacy or pharmacy department shall not provide any electronic equipment  
35 or apparatus to a practitioner or health care facility for the purpose of providing an incentive to  
36 the practitioner or health care facility to refer patients to a particular pharmacy or pharmacy de-  
37 partment.

38 (8) There shall be no additional charge to the patient because the prescription drug order was  
39 electronically transmitted.

40 (9) Nothing in this section shall be construed as authorizing the electronic transmission of a  
41 prescription drug order when a written prescription is required under ORS 127.815, 137.473,  
42 169.750[,] or 453.025 [or 475.185 (1)].

43